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ABSTRACT 
Schizophrenia spectrum disorders are psychiatric illnesses that have a high incidence of 
patients not adhering to their antipsychotic medications. There are multiple factors that 
contribute to medication nonadherence in patients with a schizophrenia spectrum disorders. 
Nonadherence with antipsychotic medications can cause poor patient outcomes for patients with 
these psychiatric illnesses. There is evidence to support that the therapeutic communication 
intervention, motivational interviewing, can improve medication adherence in patients with 
schizophrenia spectrum disorders. This quality improvement project used a pre- and post-test 
design to assess medication adherence pre- and post-intervention. The main outcome of this 
project was to improve the patient outcome, medication adherence. This project included a study 
sample of two participants that met inclusion criteria. Patient A’s pre-intervention medication 
adherence rating scale (MARS) score was 7 out of 10 and Patient B’s score was 4 out of 10. The 
higher the score on the MARS, the more favorable medication adherence. Patient A was unable 
to receive a therapeutic session of motivational interviewing because he was acutely psychotic 
and paranoid. Patient B received one face-to-face motivational interview session and behavioral 
changes were discussed on how to maintain medication adherence. The one-month follow up 
post- intervention could not be completed due to appointments being rescheduled by the patients 
and provider. The post-intervention MARS were not completed and motivational interviewing 
was unable to be evaluated for effectiveness. Despite the lack of result findings on medication 
adherence, administering the MARS and utilizing motivational interviewing offered insight 
about the patient’s beliefs and feelings about their antipsychotic medication. It is recommended 
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for future projects to expand the PDSA cycle to recruit more participants and fully implement the 
study protocol.  
Keywords: motivational interviewing, medication adherence, schizophrenia spectrum disorders, 
and therapeutic communication. 
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INTRODUCTION 
Schizophrenia affects 1.1% of Americans or about 2.6 million adults, with 40% of these 
individuals being untreated (Treatment Advocacy Center, 2018c). Schizophrenia spectrum 
disorders includes schizophrenia, psychosis, schizoaffective, schizophreniform, delusional, and 
schizotypical (personality) disorder (American Psychiatric Association [APA], 2013). This 
Doctor of Nursing Practice (DNP) project will address schizophrenia spectrum disorders, 
specifically schizophrenia and schizoaffective disorder. 
The diagnostic criteria for schizophrenia is having two or more of the following 
symptoms present for a majority of a one-month period: delusions, hallucinations, disorganized 
speech, disorganized or catatonic behavior (APA, 2013). These symptoms must also be causing a 
decline in functioning in one or more including work, school, relationships, or self-care (APA, 
2013). Symptoms must also persist for six months, other disorders have been ruled out, and the 
symptoms are not attributed to the effects of a medical condition or substance use (APA, 2013). 
To meet diagnostic criteria for schizoaffective disorder, the person must present with two 
or more symptoms of schizophrenia for an uninterrupted period of one month (APA, 2013). In 
addition to having delusions or hallucinations for two or more weeks without a major mood 
episode of either depression or mania (APA, 2013). Symptoms of depression or mania must be 
present for the entire duration of the psychotic disorder and symptoms cannot be attributed to a 
substance (APA, 2013). Schizoaffective disorder can be either bipolar or depressive type (APA, 
2013). 
There are multiple factors that enhance the quality of care of patients who experience 
psychotic symptoms. One significant care enhancing technique is therapeutic communication, a 
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technique that builds a professional and trusting relationship between patients and their 
healthcare provider. Effective and therapeutic communication are critical skills for healthcare 
providers when working with patients and is even more significant for patients with 
schizophrenia spectrum disorders. The healthcare provider uses therapeutic communication to 
influence or help the patient come to a better understanding of their illness and treatment options 
contribute to the therapeutic relationship (Mosby, 2017). Specific strategies may be used to urge 
the patient to convey feelings or ideas of acceptance (Mosby, 2017), such as with their diagnosis 
and treatment plan, as good therapeutic communication leads to a better therapeutic relationship 
and improved medication adherence in patients with schizophrenia spectrum disorders (Jaeger, 
Weißhaupt, Flammer, & Steinert, 2014; McCabe et al., 2012). 
A poor therapeutic relationship between the prescriber, poor insight and lack of 
knowledge, and coercion to take medication have an undesirable effect on treatment outcomes 
for schizophrenia spectrum disorders (Lincoln et al., 2016). Another contributing factor to 
nonadherence of medications in patients with schizophrenia spectrum disorders is poor 
communication (Misdrahi, Petit, Blanc, Bayle, & Llorcas, 2012; Wade, Tai, Awenat, & Haddock, 
2016; Velligan, Sajatovic, Hatch, Kramata, & Docherty, 2017). Whereas a positive therapeutic 
relationship between healthcare providers and patients with schizophrenia spectrum disorders is 
associated with better antipsychotic medication adherence (McCabe et al., 2012). 
The primary medications for treating schizophrenia and psychosis of schizoaffective 
disorder are first generation ‘typical’ antipsychotics and second-generation ‘atypical’ 
antipsychotics and typically, when a patient starts on antipsychotic therapy for psychotic 
symptoms, this becomes a life-long treatment (Lally & MacCabe, 2015; Zhang, 2016). The 
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benefits of antipsychotics are symptom management and improved quality of life (Zhang, 2016). 
Antipsychotic medications reduce the symptoms of schizophrenia and psychosis, such as 
auditory and visual hallucinations, paranoia, delusions, and disorganized behavior and thinking 
(Zhang, 2016). Symptoms of schizophrenia affect the patient’s functioning, productivity, may 
cause aggression, agitation, and may lead to self-harming and institutionalization (Zhang, 2016). 
Antipsychotic medications help manage the illness, and allow patients to integrate within the 
community (Zhang, 2016). 
Medication adherence, also interchangeably used with the term medication compliance, 
is defined as taking medication as prescribed (Haddad et al., 2014). Medication adherence is 
important for the treatment and mental well-being of people with schizophrenia spectrum 
disorders. In contrast, nonadherence refers to times when patients are not adhering to the 
prescribed recommendations. Nonadherence may also be used interchangeably with 
noncompliance. Nonadherence can occur when people completely stop taking their medications 
as prescribed, or the patient only occasionally takes the medication, or has missing doses 
(Haddad et al., 2014). Many issues can arise for people with psychosis not adhering to their 
medication regimens. Medication nonadherence in people with schizophrenia can lead to an 
increase risk of relapse, readmission into hospitals, and even death (Higashi et al., 2013). Other 
consequences of nonadherence for people with schizophrenia disorders are homelessness, 
incarceration, suicide attempts, suicide deaths, and homicide involving a person with serious 
mental illness (Treatment Advocacy Center, 2018b). 
One method that has been shown to increase adherence or compliance with medications 
is motivational interviewing, a therapeutic communication intervention. Motivational 
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interviewing utilizes three communication styles in healthcare, which are directing, guiding, and 
following (Rollnick, Miller, & Butler, 2007). Directing is an approach for the provider to take 
charge in the session by communicating and offering knowledge and expertise to the situation 
(Rollnick et al., 2007). Guiding involves the healthcare provider assisting the patient and making 
alternative suggestions to behavioral change by asking the patient how the healthcare provider 
can assist the patient (Rollnick et al., 2007). Following involves the healthcare provider listening 
to the patient and following along with what they say by communicating support and trust in the 
patient’s decisions to make a change (Rollnick et al., 2007). These three communication styles 
may also be used interchangeably with one another and adapted to the individual patient needs 
(Rollnick et al., 2007). 
Three communication skills that can make these communication styles more effective are 
asking, listening, and informing (Rollnick et al., 2007). The provider must ask the patient 
questions in order to better understand the problem and listen attentively (Rollnick et al., 2007). 
Healthcare providers can show that they are actively listening to their patients by paraphrasing, 
using verbal affirmations, seeking clarifications, and nonverbal language. Patients must also be 
informed of their illness and the importance of appropriate treatment for their health and well- 
being (Rollnick et al., 2007). If informing does not take place, this can result in poor adherence 
to treatment (Rollnick et al., 2007). 
Healthcare providers who use these motivational interviewing communication styles and 
skills, can collaborate with the patients with schizophrenia spectrum disorders and make shared 
decisions on treatment. Engaging the patient in this therapeutic manner gives patients a sense of 
empowerment in their care and skills to develop their own motivation to make necessary changes 
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to improve antipsychotic medication adherence. Thus, this project utilized these communication 
styles and skills of motivational interviewing to emphasize to the patients with schizophrenia 
spectrum disorders, the importance of antipsychotic medication adherence 
Significance 
Using motivational interviewing as a form of therapeutic communication in the mental 
healthcare setting, advanced practice nurses can help improve patient outcomes and associated 
healthcare costs resulting from readmissions to hospitals. Some 80% of people with 
schizophrenia who stop taking their medications compared to 30% of those who are compliant 
with their medications will experience a relapse of psychotic symptoms within a year (Treatment 
Advocacy Center, 2018c).The economic burden of schizophrenia on the U.S. was $155.7 billion 
with $37.7 billion in healthcare costs in 2013 (Cloutier et al., 2016). This amounts to a cost of 
$44,773 per individual with schizophrenia (Fuller, 2016). The cost of schizophrenia on the U. S. 
economy was last reported in 2002 and was estimated at $62.7 billion (Fuller, 2016). These costs 
could be reduced if more patients with schizophrenia spectrum disorders took their antipsychotic 
medications in congruence with the definition of medication adherence. The significance for 
patients with schizophrenia spectrum disorders to adhere to their antipsychotic medications is so 
they may have an improved quality of life (Zhang, 2016).  
Local Problem 
In Arizona, the estimated number of people with schizophrenia in 2017 was 59,000 
(Treatment Advocacy Center, 2018a). There is little research, within Arizona or at this clinic, on 
the use of motivational interviewing with patients with schizophrenia spectrum disorders who are 
nonadherent to their medications. As a registered nurse in an inpatient clinical setting and as an 
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advanced practice nurse student, I am aware that many healthcare providers with patients with 
schizophrenia spectrum disorders to encourage medication adherence do not use motivational 
interviewing. The lack of use of motivational interviewing in the care and treatment of patients 
which schizophrenia spectrum disorder justifies the need for, as well as the significance of this 
DNP project as a mechanism to provide greater understanding and evidence on the use of 
motivational interviewing for this population.  
The target population are the adult patients with schizophrenia spectrum disorders who 
are prescribed antipsychotic medications at a local outpatient clinic, Strategic Mental Health, in 
Phoenix, Arizona. There are currently 123 patients in an active status at the Strategic Mental 
Health clinic with a diagnosis of schizophrenia and 248 active patients with a diagnosis of 
schizoaffective disorder. Of the 123 patients with schizophrenia, 29 patients have continued to 
seek medication management at the clinic for their schizophrenia in the year 2019. Out of the 
248 patients with schizoaffective disorder, 62 patients (in 2019) seek medication management 
for their mental illness.  
Purpose, Aim and Objective 
The purpose of this DNP project was to implement motivational interviewing with 
patients with schizophrenia spectrum disorders to improve medication adherence at the 
outpatient psychiatric clinic, Strategic Mental Health. The advanced practice nursing student 
used motivational interviewing to enhance therapeutic communication with patients with 
schizophrenia spectrum disorders and emphasized the importance of antipsychotic medication 
adherence. The objective was to evaluate if motivational interviewing was effective in improving 
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medication adherence in a subsample of persons diagnosed with schizophrenia and 
schizoaffective disorder. 
Stakeholders are important to the development and implementation of the project. The 
stakeholders involved in this project included the participating patients, the chief psychiatric 
mental health nurse practitioner of the three locations of the clinic, the committee members of 
the project, and the author of the project. Each stakeholder brought a unique aspect to the quality 
improvement project. The intent of the patients participating in this project was to aid in quality 
improvement of this clinical problem and for future evidenced- based practice. The psychiatric 
provider and committee members of this project provided knowledge and resources for 
successful implementation of the intervention and working with the participating patients. The 
author of this project has analyzed evidence of the motivational interviewing intervention. This 
author then formulated and disseminated the implementation and evaluation of the project. 
Study Question 
Will using motivational interviewing, as a form of therapeutic communication, increase 
adult patients with schizophrenia spectrum disorders, adherence to their antipsychotic 
medications? 
Conceptual and Theoretical Framework 
Plan-Do-Study-Act Cycle 
The framework that helped guide this DNP project was the Institute for Healthcare 
Improvement (IHI) model for improvement, plan-do-study-act (PDSA) cycle. This quality 
improvement framework is used to accelerate improvement of healthcare and outcomes by 
developing, testing, and implementing change (IHI, 2019). The model consists of two parts. Part 
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one address three questions: 1) “What are we trying to accomplish?” 2) “How will we know that 
a change is an improvement?” and 3) “what change can we make that will result in 
improvement?” (IHI, 2019). These three questions create a sequence that leads to testing change. 
To answer these questions, timely and measurable aims are set that address a specific patient 
population, measures are established to evaluate if a change has led to an improvement, and a 
proposed change to implement (IHI, 2019). Once this is established, the change may be tested 
using the PDSA cycle, which is the second part to the IHI model of improvement. The PDSA 
cycle consists of four phases: 1) plan the test and how data will be collected; 2) try out the 
change by performing a small test; 3) study and analyze the data collected; and, 4) act on the 
change based upon the results (Agency for Healthcare Research and Quality [AHRQ], 2013). 
For this DNP project, the aim was to enhance medication adherence among adult patients 
with schizophrenia spectrum disorders at the end of a one-month post-intervention follow up. 
Medication adherence was the measurable outcome. The selected intervention for change was 
motivational interviewing. The “plan” phase for this project was planning the methodology and 
appraisal of evidence to support the intervention. The “do” phase was implementing motivational 
interviewing as a form of therapeutic communication between the healthcare provider and 
patients with schizophrenia spectrum disorders, on a small scale in the clinical setting chosen. 
The “study” phase of this project was performing a data analysis of the results after 
implementation of the intervention. Lastly, the “act” phase involved a discussion with 
stakeholders on the results of this DNP project and implications for future research and clinical 
practice. 
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Theory of Planned Behavior 
The theory of planned behavior (TPB) was another framework that guided this project as 
it provides the theoretical background behind human behaviors, that humans consider the 
implications of their actions, and the person’s intent to do or not to do a certain behavior will 
contribute to their actions (Ajzen, 2005). There are three types of beliefs that guide human 
behaviors: 1) A behavioral belief is the human’s subjective expectation that a behavior will 
produce an outcome; 2) the outcome will then determine the person’s attitude about the behavior 
(Ajzen, 2019); and, 3) The person will develop either a positive or negative attitude about the 
behavior depending on their belief of whether the outcome was good or bad (Health 
Communication Capacity Collaborative [HCCC], n.d). 
Normative beliefs are the behavioral expectations of specific individuals that have an 
influence on the human’s intent to engage or not engage in these behaviors due to social or peer 
pressure, as known as subjective norm (Ajzen, 2019). Lastly, control beliefs consider that there 
are certain powerful factors that may expedite or hinder the action of a behavior that leads to the 
human’s perceived behavioral control of their ability to perform a behavior (Ajzen, 2019). The 
actual ability, skills, and resources to successfully perform a behavior is actual behavioral control 
(Ajzen, 2019). Overall, the personal attitude, social influence, and issue of control are the 
motivation of the person’s intent to perform a behavior and they must find their own personal 
readiness to do so (Ajzen, 2005; 2019). Figure 1 displays the TPB diagram. 
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FIGURE 1. The theory of planned behavior diagram. (Derived from Ajzen, 2019). 
The Health Communication Capacity Collaborative (HCCC) states that implementers of 
interventions can use this theory to address an individual’s certain behavior (n.d.). In relation to 
this DNP project, this theory provided the underlying understanding of implementing 
motivational interviewing to address the behavior of medication nonadherence in patients with 
schizophrenia spectrum disorders. Through the understanding of the three beliefs of the theory 
and a person’s motivational intentions to perform a behavior, it provides the knowledge of how 
to help someone make a behavioral change (HCCC, n.d.).  
The purpose of motivational interviewing is to guide a patient in finding their own 
motivation to make a behavioral change (Rollnick et al., 2007). The healthcare provider can gain 
insight on their patients’ values, beliefs, and concerns about their medication nonadherence 
behaviors and use motivational interviewing to elicit a conversation to collaborate good reasons 
and arguments for a behavioral change (Rollnick et al., 2007). People can be willing to change if 
they have a positive attitude about the behavior and it is important to remember that there are 
certain factors that may be hindering them from making the change. Barriers must be identified 
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such as; negative attitudes, subjective norms, and the individual’s ability to perform a behavior 
for the change to take place (HCCC, n.d.). Discussing barriers and ambivalence about 
medication adherence is a part of the collaboration and therapeutic communication that 
motivational interviewing offers between healthcare providers and patients. 
In using motivational interviewing, the healthcare provider must listen to the patient’s 
perception on their reasoning for medication nonadherence and motivation for change by asking 
if they want to and how they would make a change rather than telling them how they should 
(Rollnick et al., 2007). This focuses on gaining the patient’s attitude and intent to change. 
Ultimately, the therapeutic communication between the healthcare provider and the patient using 
motivational interviewing empowers the patient to develop their own ideas and resources to 
make the necessary behavioral changes with the healthcare provider’s support (Rollnick et al., 
2007).  
Motivational Interviewing  
The goal of motivational interviewing is for the healthcare provider to assist a patient to 
make behavioral changes to promote a better and healthier lifestyle, using their internal 
motivation. The patient must be “… willing, able and ready …” to change (Barkhof et al., 2006). 
Motivational interviewing differs from provoking persuasion, arguments, and becoming 
confrontational with the patient, and instead the focus is on providing empathetic, respectful, 
non- judgmental, and reflective listening for the patients’ perspective on changing behaviors 
(Barkhof et al., 2006). The healthcare provider utilizing motivational interviewing must present 
to the patient discrepancies in their current behaviors and encourage the patient to develop their 
own reasons for change (Barkhof et al., 2006). The healthcare provider is encouraged to roll with 
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resistance and change their approach in helping patients identify changing behaviors that they are 
not ambivalent about (Barkhof et al., 2006). The healthcare providers are urged to support the 
patients’ self-efficacy to make the behavioral change (Barkhof et al., 2006). 
This psychological intervention will provide therapeutic communication between the 
healthcare provider and patients with schizophrenia spectrum disorders. Motivational 
interviewing will allow the patients with schizophrenia spectrum disorders to better understand 
the need and importance of medication and formulate their own ideas on modifying their feelings 
and thoughts about antipsychotic medications, and make a change to their nonadherent 
behaviors. 
This project director received continuing education and training on the foundation, 
evidence as well as the communication skills and processes of motivational interviewing. The 
education and training included two modules that introduced motivational interviewing and the 
coaching skills and process of this intervention. The University of Arizona offered the training as 
12 continuing education credits (EC). Certificates were awarded for completion of the training 
(Appendices A & B). 
With the completion of the motivational interviewing course, this author implemented the 
intervention during a medication management session with the patient. The technique of 
motivational interviewing during the session intended to encourage the patients to reevaluate 
their beliefs on the importance of their medications and make the necessary behavioral changes. 
Having an established relationship with the patient after becoming acquainted in the outpatient 
clinical setting, where the project will take place, will also be an advantage.  
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Literature Review 
A comprehensive literature review was performed to synthesize the best evidence based 
research for application and implementation into clinical practice. Using systematic methods, 
scholarly articles were searched on PubMed, CINAHL, and PsychINFO. The following key 
search terms were used: “schizophrenia,” “medication nonadherence” or “adherence,” 
“medication noncompliance” or “compliance,” “therapeutic communication” or “relationship” or 
“alliance,” and “motivational interviewing.” Search criteria was limited to adult participants, 
ages 18 and older, the English language, articles from the publication dates 2010 to 2019, text 
availability was limited to full text, and search terms were filtered to the title and abstract. This 
yielded 10 articles to be considered for evidentiary support in this project. The study designs of 
these articles include, one randomized controlled trial (RCT), one quasi-experimental study with 
a pre- and post-test design, one case study, one cross sectional study, one observational study, 
one multi-centre study, one literature review, and three systematic reviews (Chien et al., 2015; 
Dikec & Kutlu, 2015; El-Mallakh & Findlay, 2015; Ertem & Duman, 2016; Higashi et al., 2013; 
Jaeger et al., 2014; Mallisham & Sherrod, 2017; McCabe et al., 2012; Velligan et al., 2017; 
Wade et al., 2017). Table 1 displays the appraisal of all articles reviewed. 
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TABLE 1. Evidence appraisal table. 
Author / 
Article 
Qualitative: 
Concepts or 
Phenomena 
Quantitative: Key 
Variables 
Hypothesis 
Research Question 
Theoretical 
Framework 
Design Sample (N) Data Collection 
(Instruments/Tools) 
Findings 
Chien, Mui, 
Cheung, & Gray 
(2015). Effects of 
motivational 
interviewing-based 
adherence therapy 
for schizophrenia 
spectrum disorders: 
A randomized 
controlled trial 
Hypothesis: 
To test and evaluate if 
adherence therapy (AT) 
using motivational 
interviewing (MI) is 
effective on outpatients 
with schizophrenia 
spectrum disorders over a 
six- month follow up 
 
Variables: 
Medication adherence 
Symptom Severity 
Insight into treatment 
Hospitalization rate 
Level of functioning 
 
None stated. Single blind, 
Randomized 
controlled 
trials (RCT) 
N=114 
AT=57 
Treatment as 
usual 
(TAU)=57 
Baseline and post 6 
months; 
Positive and Negative 
Syndrome Scale (PANSS) 
 
Insight and 
Treatment Attitude 
Questionnaire (ITAQ) 
 
Adherence 
Rating Scale (ARS) 
 
Frequency and length 
(days) of psychiatric re-
hospitalizations 
 
Specific Level of 
Functioning Scale (SLOF) 
 
Overall findings 
resulted in 
improvements of the 
five measurable 
outcomes when MI 
was used for a six-
month period. 
Dikec & Kutlu 
(2015). 
Effectiveness of 
adherence therapy 
for people with 
schizophrenia in 
turkey: A 
controlled 
Hypothesis:  
The patients with 
schizophrenia that receive 
adherence therapy will 
have high scores on 
treatment adherence,   
None stated.  Quasi-
experimental 
design with a 
pretest–
posttest  
 
N=30 
Experimental 
(n=15)- 
received 8 
sessions of 
adherence 
therapy 
Questionnaire Form  
Medication  
 
Medication Adherence 
Rating Scale (MARS)  
 
 
Adherence therapy 
was effective at 
improving medication 
adherence, but only at 
the posttest scores of 
the MARS. Adherence 
therapy did not 
improve insight or  
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TABLE 1 – Continued  
Author / Article Qualitative: 
Concepts or 
Phenomena 
Quantitative: Key 
Variables 
Hypothesis 
Research Question 
Theoretical 
Framework 
Design Sample 
(N) 
Data Collection 
(Instruments/Tools) 
Findings 
study. insight and internalized 
stigma than the 
controlled group of 
patients with 
schizophrenia that did 
not receive adherence 
therapy.  
 
Adherence therapy 
consisted of MI and 
cognitive- behavioral 
techniques.  
 
  Control 
(n=15) 
Internalized Stigma of 
Mental Illness Scale 
(ISSMI)  
 
Beck Cognitive Insight 
Scale (BCIS) 
internalized stigma. 
El-Mallakh & Findlay 
(2015). Strategies to 
improve medication 
adherence in patients 
with schizophrenia: 
The role of support 
services 
Support services that 
promote medication 
adherence in mental 
health patients 
diagnosed with 
schizophrenia 
None stated. Literature 
Review: 22 
articles 
included 
Not 
applicable.  
Not applicable.  Many support service 
interventions were found to 
aid in medication adherence, 
one of them being MI. Three 
out of four articles reviewed 
on MI showed evidentiary 
support for medication 
adherence, symptom 
management, and patient’s 
attitudes on medication. 
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TABLE 1 – Continued  
Author / Article Qualitative: Concepts 
or Phenomena 
Quantitative: Key 
Variables 
Hypothesis 
Research Question 
Theoretical 
Framework 
Design Sample 
(N) 
Data Collection 
(Instruments/Tools) 
Findings 
Ertem & Duman 
(2016). Motivational 
interviewing in a 
patient with 
schizophrenia to 
achieve 
treatment 
collaboration: A case 
study 
Enhance treatment 
collaboration using MI for a 
patient with schizophrenia 
who is resistant to treatment 
None stated. Case study; 
45 minutes of 
MI once a 
week for 6 
weeks 
N=1 Administered at baseline 
and at 6 week interview: 
Morisky Medication 
Adherence Scale (MMAS) 
 
Drug Attitude Inventory 
(DAI) 
Patient was able to 
express his feelings of 
ambivalence towards his 
medication, benefited 
from MI in understanding 
the importance of 
medication adherence, 
and complied with 
treatment. 
 
Higashi et al. (2013).  
 Medication 
adherence in 
schizophrenia: factors 
influencing adherence 
and consequences of 
nonadherence, a 
systematic literature 
review 
Determined factors that 
influence adherence of 
medications and what are 
the consequences of 
nonadherence on the 
schizophrenia spectrum 
disorder patient, healthcare 
system, and society 
None stated.  Systematic 
Review: 37 
articles 
included  
Not 
applicable.  
Not applicable. 
 
Nonadherence of 
medications in the 
schizophrenic population 
can include the patient’s 
lack of insight, their 
beliefs on medications, 
and substance abuse. 
 
Nonadherence can lead to 
relapse, hospitalization, 
and suicide.  
Positive factors that 
influence medication 
adherence are positive  
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TABLE 1 – Continued  
Author / Article Qualitative: 
Concepts or 
Phenomena 
Quantitative: Key 
Variables 
Hypothesis 
Research Question 
Theoretical 
Framework 
Design Sample 
(N) 
Data Collection 
(Instruments/Tools) 
Findings 
      therapeutic 
relationships with the 
provider and the 
perceived benefits the 
medication can offer. 
 
Jaeger, Weißhaupt, 
Flammer, & Steinert 
(2014). Control 
beliefs, therapeutic 
relationship, and 
adherence in 
schizophrenia 
outpatients: 
A cross-sectional 
study 
Hypotheses: 
Both powerful 
others and internal health 
locus of control (HLC) 
and the patient–doctor 
relationship are 
associated with 
medication adherence 
 
Powerful others HLC 
associates with a trusting 
therapeutic relationship, 
but is not associated 
between the therapeutic 
relationship and internal 
HLC 
 
Theory of 
social learning 
Cross- 
sectional 
study 
N=69 Self-rating scales 
Medication Adherence Rating Scale 
(MARS) 
 
Fragebogen zur Erhebung von 
Kontrollüberzeugun genzu Krankheit 
und Gesundheit (KKG) a German 
questionnaire that is based on the 
Multidimensional Health Locus of 
Control (MHLC) scale 
 
Scale to Assess Therapeutic 
Relationships in Community Health 
Care, patient version (STAR-P) 
The therapeutic 
relationship between 
the provider and patient 
and the patient’s 
attitudes and beliefs 
about their medications 
was highly correlated 
with medication 
adherence. 
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TABLE 1 – Continued  
Author / 
Article 
Qualitative: 
Concepts or 
Phenomena 
Quantitative: Key 
Variables 
Hypothesis 
Research 
Question 
Theoretical 
Framework 
Design Sample 
(N) 
Data Collection 
(Instruments/Tools) 
Findings 
 The therapeutic 
relationship facilitates 
the effect of the 
powerful others HLC 
preference for 
medication adherence 
 
     
Mallisham & 
Sherrod (2017). 
The spirit and intent 
of motivational 
interviewing 
Educate HCPs on 
improving their 
communication skills 
with psychiatric 
patients using MI 
None stated.  Observational 
study  
N=61 MI training- Eight hour course, 
weekly, for six weeks on the MI 
course content; (comMIt) to assess 
provider knowledge on MI and 
their communication skills, was 
given pre and posttest 
 
Motivational Interviewing 
Adherence and Competency 
Feedback (MIACF) form 
 
After three weeks of 
implementing MI with 
the psychiatric patients, 
the HCPs enhanced 
their therapeutic 
relationships and 
behavioral changes 
with their patients. 
McCabe et al. 
(2012). The 
therapeutic 
relationship and 
adherence to 
antipsychotic 
medication in 
schizophrenia 
Study on whether the 
therapeutic relationship 
had an impact on 
medication adherence 
in patients with 
schizophrenia 
None stated.  Multi- centre 
study 
N= 134 
clinicians 
and 507 
patients 
Data collected from December 
2002 – May 2004 
Therapeutic relationship assessed 
with the Helping Alliance Scale, 
patient version-(HAS-P) and 
clinician version- (HAS-C)  
 
Patients and providers 
both linked a 
therapeutic relationship 
to medication 
adherence. 
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TABLE 1 – Continued  
Author / Article Qualitative: 
Concepts or 
Phenomena 
Quantitative: Key 
Variables 
Hypothesis 
Research Question 
Theoretical 
Framework 
Design Sample 
(N) 
Data Collection 
(Instruments/Tools) 
Findings 
     Medication Adherence- 
Buchanan criteria 
 
Symptoms assessed- 
PANSS 
 
 
Velligan, Sajatovic, 
Hatch, Kramata, & 
Docherty, (2017).  
Why do psychiatric 
patients stop 
antipsychotic 
medication? A 
systematic review of 
reasons for 
nonadherence to 
medication in patients 
with serious mental 
illness 
Examined the different 
modifiable risk factors for 
nonadherence to 
antipsychotic medications 
in patients with Serious 
Mental Illness (SMI) 
None stated. Systematic 
Review: 36 
articles 
included  
Not 
applicable.  
Not applicable.  In patients with 
schizophrenia, 
nonadherence was due to 
substance abuse and 
attitude about medication 
and adherence was linked 
to a better therapeutic 
relationship with the 
provider. 
Wade, Tai, Awenat, & 
Haddock, (2017). A 
systematic review of 
service-user reasons for 
adherence and 
nonadherence to 
neuroleptic medication 
in psychosis 
Reasons for neuroleptic 
medication nonadherence 
and adherence in patients 
with schizophrenia 
spectrum disorders 
None stated.  Systematic 
Review: 21 
articles 
included 
Not 
applicable  
Not applicable.  Factors that are 
influencing are the 
importance of 
relationships, outlook on 
illness, recovery, and 
treatment. 
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Synthesis of Evidence 
Much of the evidence supports that improving therapeutic communication between the 
healthcare provider and patients with schizophrenia spectrum disorders can lead to a better 
therapeutic relationship and improve medication adherence (Higashi et al., 2013; Jaeger et al., 
2014; McCabe et al., 2012). Factors influencing medication nonadherence are poor therapeutic 
communication and relationships between this patient population and their provider (Velligan et 
al., 2017; Wade et al., 2017). Motivational interviewing is an intervention described to enhance 
therapeutic communication (Mallisham & Sherrod, 2017). Healthcare providers educated on 
motivational interviewing who used this intervention with psychiatric patients, exhibited 
enhanced therapeutic communication skills, relationships, and behavioral changes with the 
patients (Mallisham & Sherrod, 2017). 
Motivational interviewing increases medication adherence among patients with 
schizophrenia spectrum disorders (Chien et al., 2015; Dikec & Kutlu, 2015; Ertem & Duman, 
2016). Motivational interviewing has been found to improve symptoms, increase insight into 
illness, reduce the number of re-hospitalizations, and enhance level of functioning (Chien et al., 
2015). Improving symptom management, gaining insight into illness, and improving the level of 
functioning are very significant factors that enhance quality of life for these patients. In addition, 
medication adherence may improve, thereby reducing symptom relapse, re-hospitalizations, and 
fatalities (Higashi et al., 2013). Motivational interviewing has also shown evidentiary support 
towards medication adherence, symptom management, and changing the patient’s attitude about 
their medications (El-Mallakh & Findlay, 2015).  
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Strengths, Limitations and Gaps 
Chien et al. (2015) conducted a RCT using motivational interviewing. The study had 
many strengths due to the large sample size of 114 participants, study design, and positive results 
found for medication adherence and other outcomes following the implementation of 
motivational interviewing. However, a weakness was generalizability because the participants 
were only of Chinese culture and background. 
A significant limitation to the research is small sample sizes. Although the case study 
included in the evidence appraisal table demonstrated medication improvement with 
motivational interviewing, it consists of only one patient (Ertem & Dumcan, 2016). The small 
sample size also limits generalizing the findings to a larger population (Ertem & Dumcan, 2016). 
Despite only one case, the study had intervention fidelity, which is a strength to support the 
evidence findings that motivational interviewing led to an effective communication process and 
should encourage healthcare providers to consider applying motivational interviewing in their 
practice for medication management and adherence (Ertem & Dumcan, 2016). 
Biases can also be a limitation in research. The providers who participated in McCabe et 
al.’s (2012) study rated their patients’ medication adherence and their relationships with those 
patients. The use of self-rated instrumental tools for assessing medication adherence may skew 
results, as patients can tend to overestimate their adherence (Jaeger et al., 2014). In addition, if 
there are other therapies used during the study other than just motivational interviewing this can 
also skew results (Dikec & Kutlu, 2015). 
More extensive studies using a RCT design are needed in regards to this topic. RCTs are 
considered Level I of high quality evidence that provides consistent and generalizable results, a 
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sufficient sample size, adequate control, solid conclusion, and scientific evidence (Johns Hopkins 
Hospital, 2017). Future studies should also include the need to reduce biases by the use of more 
objective measures instead of the use of self-reported measures. Medication adherence can also 
be evaluated with the use of more objective measures such as blood tests, pill counts, and 
electronic monitoring (McCabe et al., 2012; Jaeger et al., 2014). 
Overall, the literature supports using motivational interviewing to enhance therapeutic 
communication with patients with schizophrenia spectrum disorders and gain medication 
adherence. Although the evidence from the literature cannot be generalized to a large population, 
for the purpose of this DNP project, the use of motivational interviewing with a small sample 
size of patients with schizophrenia spectrum disorders may influence positive results in 
medication adherence.  
METHODS 
Design 
The purpose of this DNP project was to implement motivational interviewing with 
patients with schizophrenia spectrum disorders, by therapeutically communicating the 
importance of their antipsychotic medications, to improve medication adherence. The design of 
this quality improvement project was a descriptive pre and post-test design. Participants were 
assessed before and after implementing motivational interviewing.  
Participants 
The participants were selected by performing a chart review of the electronic medical 
record. The inclusion criteria for this project were patients who were 18 and older who had a 
diagnosis in the schizophrenia spectrum that meets the DSM-V criteria, specifically 
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schizophrenia and schizoaffective disorder. The patients must have been receiving medication 
management at the local clinical setting from the nurse practitioner preceptor of this DNP 
student. In addition, each patient participant was English speaking, and currently prescribed 
antipsychotics to treat their type of schizophrenia. The exclusion criteria were pregnant patients, 
non-English speaking, patients with guardians and/or power of attorneys, and those that are 
actively suicidal, homicidal or experiencing an acute psychiatric emergency. The advanced 
practice student was treating seven potential participants that met these criteria. 
Setting 
The setting for this project took place among the three outpatient psychiatric clinics, 
named Strategic Mental Health, in the Phoenix area of Arizona. Strategic Mental Health offers 
psychiatric services for medication management and psychotherapy for many psychiatric, mental 
health, and addiction disorders. One psychiatrist, psychiatric mental health nurse practitioners 
(PMHNPs), licensed counselors and social workers, staffs the clinics. This setting is the clinical 
rotation site of the DNP student/project director. 
Motivational Interviewing Intervention 
Motivational interviewing is a patient-centered intervention that is utilized by healthcare 
providers in assisting patients to recognize problems in the self- management of their illness. 
Motivational interviewing also helps strategize ways in which patients can make behavioral 
changes and committing to changes for improving their own health and wellness (Barkhof et al., 
2006). Motivational interviewing should be done in an empathetic and supportive manner that 
remains non-judgmental (Barkhof et al., 2006). The goal of motivational interviewing is for the 
patient to recognize a problem and build the internal motivation to make a change (Barkhof et 
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al., 2006). The patient must also be willing and ready to make the change (Barkhof et al., 2006). 
This form of therapeutic communication between the provider and patient can help strengthen 
the therapeutic relationship and potentially reduce or eliminate ambivalence. 
The motivational interviewing session will consist of expressing empathy, develop 
discrepancy, roll with resistance, and support the patient’s self-efficacy (Barkhof et al., 2006). 
This DNP project director used these principles by providing an empathetic and non-judgmental 
environment. The patient’s perspective on any nonadherent behaviors concerning their 
antipsychotic medications was respected and heard (Barkhof et al., 2006). The patient was 
encouraged to share their ideas and beliefs on their antipsychotic medications and making 
behavioral changes. It was the responsibility of this DNP project director to recognize and 
express any discrepancies noted between the patient’s current behaviors, thoughts, and beliefs 
(Barkhof et al., 2006). If the patient had any ambivalence or resistance to change these feelings 
will be acknowledged and the patient will be informed that these feelings are “natural and 
understandable” (Barkhof et al., 2006). After the patient had identified strategies for behavioral 
change to improve adherence to their antipsychotic medications, this DNP project director 
provided support and encouragement for the patient to make these changes (Barkhof et al., 
2006). 
Measure 
Medication Adherence Rating Scale  
The medication adherence rating scale, (MARS) (Appendix C), consists of 10 ‘yes’ and 
’no’ questions that asks the patient to best describe their behavior and attitude towards their 
medication (Thompson, Kullkarni, & Sergejew, 2000). The questions are separated into three 
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dimensions: Questions 1 to 4 address the patient’s medication adherence behavior, questions 5 to 
8 address the patient’s attitude toward taking medication, and questions 9 and 10 address 
negative side effects and the patient’s attitude toward psychotropic medications (Owie, Olotu, & 
James, 2018). The MARS is scored by adding up each item of each dimension (Owie et al., 
2018). Responses that indicate nonadherence are coded with a ‘0’ and answers that are indicative 
with medication adherence are coded with a ‘1’ (Owie et al., 2018). Specifically questions 1 to 6, 
9 and 10 that are answered no, signifies adherence and is coded a ‘1’ (Owie et al., 2018). 
Questions 7 and 8, a yes response signifies adherence and are coded a ‘1’ (Owie et al., 2018). 
The MARS total scores ranges from 0-10, with higher scores indicating more favorable 
medication adherence (Owie et al., 2018). 
The reliability and validity of this scale was confirmed through a study of 66 patients 
with schizophrenia spectrum disorders or psychosis (Thompson et al., 2000). Using Cronbach’s 
alpha, the MARS had reliable internal consistency of 0.60 (Thompson et al., 2000). Concurrent 
validity was demonstrated in the MARS total scores with low but statistically significant 
correlations (r = .18, p = .011; Thompson et al., 2000). The researchers used the drug attitude 
inventory (DAI) and the medication adherence questionnaire (MAQ) and found several 
deficiencies, which led to the development and testing of the MARS questionnaire (Thompson et 
al., 2000). The MARS had greater validity measuring adherence to psychoactive medications in 
the clinical setting than the DAI and MAQ (Thompson et al., 2000). A study conducted in 
Nigeria concluded that the MARS had good reliability, with a Cronbach's alpha of 0.76, and is a 
useful tool for assessing medication adherence in patients with schizophrenia (Owie et al., 2018). 
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Owie et al. (2018) demonstrated that the MARS showed good significance despite a weak 
external validity psychopathology and insight (p<0.001). 
Self-reported methods for assessments are commonly used but can be one of the least 
reliable methods as patients may fabricate information (Lam & Fresco, 2015). However, they are 
easy to use, can be administered in many forms, low cost, and provide real time feedback (Lam 
& Fresco, 2015). It also provides insight to the healthcare provider on the patients’ beliefs and 
concerns in regards to their medications (Lam & Fresco, 2015). This could allow for better 
communication on the importance of medication adherence and involving the patient in their 
treatment, which is the purpose of utilizing motivational interviewing in this project. The goal for 
this project was motivational interviewing would improve the scores of the MARS upon post-
intervention, which will indicate improved mediation adherence. 
Data Collection Procedure 
This DNP student performed a chart review with the nurse practitioner preceptor’s 
assistance and access. Patients were approached during a one-month time frame for recruitment. 
Two patients approached during one of their follow up appointments were given a disclaimer that 
explained the purpose and aim of this project and the goal of motivational interviewing. The 
patients were made aware that they did not need to decide at that time their intent for 
participation. If patients were undecided, they were offered a one-week time frame to contact the 
clinic office to schedule an appointment to participate in a motivational interviewing session. The 
one-week time frame allowed potential participants to review the disclaimer, provide patients the 
opportunity to contact the DNP student with any questions, decide if they wanted to participate, 
and allowed a set timeframe for a decision and feedback. If the patients did not agree to a one-
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month follow up or contact the clinic within a week, they were not included in the project. The 
two participants that were approached during recruitment agreed to a one month follow up post- 
intervention follow-up and each consented to participate. 
Data on medication adherence was collected pre- intervention and was intended to upon 
the one-month post-intervention by using the MARS. Findings were based solely on what is 
found by using the MARS. The MARS was de-identified by labeling the assessment forms, 
“Patient A or B” going in alphabetical order. The purpose of this was to compare the pre and 
post intervention scores and ensure confidentiality of the responses. At the time of provided the 
disclaimer, two participants were provided with the MARS to complete. The patient’s answers to 
the MARS guided the therapeutic approach of motivational interviewing for the purpose of 
making behavioral changes and improving medication adherence. Patients only received one 
session of motivational interviewing, which began after the completion and scoring of the MARS. 
Motivational interviewing sessions are typically only one to two sessions (Hettema, Steele, & 
Miller, 2005). However, motivational interviewing is patient-centered and can be used with many 
healthcare illnesses (Rollnick et al., 2007). The literature on motivational interviewing indicates 
that the number of motivational interviewing sessions varies. 
After the motivational interviewing session, the patients were scheduled a one-month 
follow-up appointment. At the one month follow up appointment, the intent was to have any 
returning participants complete the MARS again, it would have been scored in front of the patient, 
and the results were to be discussed comparing the pre- and post-intervention scores. Patients 
were not billed for this short follow-up, as permissible by the nurse practitioner. Success of the 
intervention on improving medication adherence was intended to be based upon the patient’s 
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self-report on the MARS. Any continued lack of medication adherence despite the intervention 
was to be further discussed with the PMHNP preceptor, who was managing the patients care and 
supervising this DNP student. 
Data Analysis 
The study variable of this project was medication adherence. The effects of the 
intervention, motivational interviewing, were analyzed and results provided from the findings of 
the data collected from the MARS on medication adherence. Data scores of the MARS from the 
pre-intervention were compared to the data scores of the MARS in the post-intervention and a 
descriptive analysis provided, that explains and compares the results. The plan for analysis was 
determined based upon the scoring guidelines of the MARS previously discussed.  
The financial analysis for this project included printing the MARS on paper for the 
purpose of data collections and there was no cost to obtaining the MARS. The time to complete 
this project is considered donated, as it is required of the DNP student to receive the degree. 
Ethical Considerations 
Authorization from the chief psychiatric nurse practitioner of the clinic to access the 
patients’ medical records and perform the project within the three clinic locations was obtained 
in writing before initiation of this DNP project (Appendix D). Patient privacy was protected 
through the Health Insurance Portability and Accountability Act (HIPAA) rules of the clinic. The 
patients’ privacy was protected, as there were no patient identifiers on the assessment tool forms 
completed by the participants. The ethical principles of autonomy, beneficence, and justice were 
followed during the implementation of this project. This quality improvement project respected 
the individual autonomy of the patients participating, which was voluntary. The patients had the 
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right to incorporate the behavioral changes discussed in the motivational interviewing session or 
not. 
The patients’ safety was not jeopardized through the implementation of this evidence-
based intervention technique to promote medication adherence. Patients included in this study, 
during their usual care, were assessed for medication adherence. There were minimal risks for 
harm. This project had the potential to benefit the participants and had potential for enhancing the 
quality of care delivered at this practice setting. All participants for this project were treated fairly 
and equally as it pertains to the inclusion criteria for the project. Each participant will have the 
right to withdraw from the project at any time without consequence. The University of Arizona 
obtained approval from the Institutional Review Board (IRB) for approval of the project 
(Appendix E). 
RESULTS 
Of the 91 patients diagnosed with a schizophrenia spectrum disorder at the clinical setting, 
there were only seven eligible participants, who were under the advanced nurse practitioner 
student provider’s care, and met the inclusion criteria. In the one-month period of recruitment and 
implementation of this project, only two eligible patients were able to participate in this project. 
Four other potential participants were eligible for participation in this project during the time of 
recruitment. Unfortunately, due to appointment cancellations by the provider and/ or patients and 
rescheduling of appointments to later dates outside of the recruitment period, these patients were 
not able to participate in the project. One other eligible participant had not had an appointment for 
his medication management through the clinical setting since February 2019 and did not have a 
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future appointment set up. This limited the number of participants to 29% of those eligible; in 
other words, only two out of the seven patients were approached and agreed to participate. 
Participants in this study were both males, with an age range of 20 to 47 years, and 
relationship status were single and married. The education status of the participants are some or 
completed college with one disabled and one employed participant. Diagnoses were both 
schizoaffective disorder, bipolar type and both prescribed antipsychotic medication. 
According to medical records, both patients have been adhering to their antipsychotic 
medications for the past few months. The pre-intervention MARS completed by participants 
before implementing the motivational interviewing session indicated some level of nonadherence. 
Patient A scored 7 out of 10 on the MARS, indicating higher medication adherence, compared to 
Patient B who scored 4 out of 10, indicating lower medication adherence. According to their 
responses on the MARS, both patients believed that it is not natural for their minds or bodies be 
controlled by medication, the medication made them feel tired, and they did not think that their 
thoughts are any clearer being on medication. Patient B also responded that after taking the 
medication, when starting to feel better or feeling worse, Patient B would stop taking the 
antipsychotic medication. Patient B indicated on the MARS that the antipsychotic medication 
gave the feeling of acting like a ‘zombie.’ 
Patient A’s motivational interviewing session was not completed due to acutely present 
psychosis and paranoia. The patient was disorganized with his thoughts and speech, which did not 
provide an accurate or effective session for motivational interviewing. The patient admitted to 
adjusting his antipsychotic medication and not taking it at the prescribed time. This patient has a 
history of nonadherence with antipsychotic medication. 
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Patient A expressed ambivalence about taking the antipsychotic medication due to how it 
makes him feel, but agreed to continue taking the medication as prescribed. The patient’s one-
month follow up appointment was rescheduled so no follow up appointment was conducted to 
have a more thorough motivational interviewing session and post- intervention administration of 
the MARS. 
Patient B received one face-to-face motivational interviewing session. During the session, 
the patient expressed his feelings about being on the medication, not liking having to take 
medications all the time, and that medication gives him the feeling of being tired. Patient did 
express that he feels less anxious, paranoid, and manic when taking the antipsychotic medication 
as prescribed. Patient B was asked what would changes his thoughts regarding his ambivalence 
towards his antipsychotic medications and what behavioral changes he could do to motivate 
himself to remain medication adherent. During the motivational interviewing session, the patient 
was encouraged to reduce any negative thoughts about the stigma of mental illness and having to 
take antipsychotic medications. The patient was encouraged to remind himself how the 
medication reduces his symptoms of his mental illness. Patient discussed ways he can modify his 
day when he is experiencing tiredness from the antipsychotic medication. The one-month follow 
up could not be completed for this patient due to scheduling issues with appointments. 
The pre- intervention MARS scores could not be compared to a post-intervention MARS 
due to incomplete follow up appointments with both patients. Therefore, the motivational 
interviewing intervention could not be evaluated for improving medication adherence between 
these two patients with schizoaffective disorder. 
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DISCUSSION 
This PDSA cycle recruited two participants from the Strategic Mental Health Clinic who 
were typical of the clinic’s population. The PDSA cycle could not be completed because there 
were no results after implementation to evaluate the effectiveness of the motivational interviewing 
intervention on medication adherence with the participants. After reviewing the results with the 
provider, it was discussed with the provider that another PDSA cycle will need to be done with 
more patients and allowing more time to complete the post-intervention evaluation. Further 
necessary changes would be to follow up with the patients that have not rescheduled an 
appointment and who meet inclusion criteria for the project, over the phone, and get a follow up 
appointment scheduled. 
The use of the MARS was a reliable and valid instrument for assessing medication 
adherence is a strength to this study. Despite the lack of results, the two participants had interest 
in some engagement and agreement to behavioral change related to medication adherence. The 
one session of motivational interviewing with these two participants indicated a positive response 
to the motivational interviewing intervention as evidenced by their engagement, verbal responses, 
and collaborative efforts. Patient A demonstrated this through verbal agreement to continue to 
take his antipsychotic as prescribed, despite ambivalence. Patient B agreed to collaborative efforts 
to making behavioral changes. It provided the provider insight into the patients’ beliefs and 
feelings regarding their antipsychotic medications and improve therapeutic communication. 
Another strength to this study were the theoretical frameworks used to guide this project. The 
intervention, motivational interviewing, has been used in evidenced based research and has shown 
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some clinical significance in improving medication adherence, which is an additional strength to 
this study. 
There are many limitations to this project as there can be no assessments made of any 
outcomes. The intervention cannot be evaluated to determine if medication adherence was 
improved post intervention. This limitation does not provide any results for if the participants’ 
behaviors changed regarding medication adherence based upon the influence of the motivational 
interviewing intervention. A major limitation of this project was the discrepancy in the 
availability of the provider and the participating patients, as there was a reoccurring account of 
rescheduling and/ or cancelling the follow up appointments. High no-show rates are quite 
common in an outpatient behavioral health clinic. It occurs with the dynamics of patients with 
mental illness and psychiatric disorders. There were also difficulties recruiting a large number of 
patients. The limitations in this project contributes to a flawed project implementation and 
suggests implications, such as recruiting more patients and allowing for longer time with the 
project for future implementation.  
DNP Essentials and Implications for Nursing Practice 
The DNP Essential I: Scientific Underpinnings for Practice provides the scientific 
foundation of natural and social sciences that are applied to guide nursing practice (American 
Association of Colleges of Nursing [AACN], 2006). This DNP student evaluated the scientific 
underpinnings of evidence from literature to support the implementation of motivational 
interviewing for medication adherence. However, the implementation and results of the 
intervention did not support further evidence to support motivational interviewing for medication 
adherence, as the project could not be successfully completed. 
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This project demonstrated the competency in Essential II: Organizational and Systems 
Leadership for Quality Improvement and Systems Thinking. This essential addresses 
organizational and systems leadership to improve patient and healthcare outcomes with safe, 
effective, and efficient care (AACN, 2006). The outpatient clinical setting used in this project 
was an attempt to utilize organizational and systems leadership to improve patient outcomes, 
such as medication adherence to antipsychotics with the patients with a schizophrenia spectrum 
disorder. Due to the lack of outcomes from the implementation process, the future design for the 
project would be to allow for more time to recruit more patients and following up post- 
intervention to determine if patient outcomes improved. 
Other DNP essentials that this project met are Essential III: Clinical Scholarship and 
Analytical Methods for Evidence-Based Practice and Essential VIII: Advanced Nursing Practice. 
A literature search using databases and a critical appraisal of evidence was performed to 
determine the support for implementation of motivational interviewing with patients with 
schizophrenia spectrum disorders. The MARS was intended to evaluate practice and patient 
outcomes. This project was designed to promote quality improvement for safe, effective, and 
patient- centered care (AACN, 2006). Gaps in the evidence were identified and discussed. 
Findings from this DNP project provide implications for future practice to expand the PDSA 
cycle to allow for more time and participants. The implementation process of this projects’ study 
design informs this DNP student, future students, and researchers to extend time for 
implementation and evaluation of outcomes when implementing a project with the mental health 
population in an outpatient setting can present issues with scheduling appointments. This will 
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deliver a better study design that will perhaps provide quality improvement to the clinical setting 
based on results. 
A comprehensive and systematic assessment of schizophrenia spectrum disorders was 
conducted in a complex situation, while remaining diverse and culturally sensitive (AACN, 
2006). This DNP project student assessed for potential participants with a psychotic disorder, a 
vulnerable population, ensuing complex integration of care and this student was supervised 
during all clinical interventions by her clinical PMHNP preceptor. This DNP project intended to 
implement and evaluate the therapeutic intervention, motivational interviewing, to develop and 
sustain a therapeutic relationship with the patients and improve medication adherence (AACN, 
2006). Clinical judgment was demonstrated using evidenced-based care of the motivational 
interviewing intervention and provide guidance and education to the patients to improve patient 
outcomes (AACN, 2006). 
Conclusion 
Due to the incomplete implementation of the intervention, there are no findings to report. 
However, multiple lessons were learned about how to implement a quality improvement project. 
In future practice, PDSA cycle length would be expanded to allow for more time for recruitment 
of participants and follow up appointments considering the inherent difficulties of patients not 
showing or rescheduling appointments. 
The DNP project did provide insight into the participant’s thoughts, feelings, and 
reasoning about their medication nonadherence. This allowed the DNP student to engage in a 
therapeutic conversation using motivational interviewing with the two participants. Major 
limitations was the inability to have a follow up appointment with the participants, attempt 
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motivational interviewing with Patient A again, and obtain a post- intervention MARS score to 
evaluate improvement in medication adherence. Future projects that use the PDSA cycle with 
increased patients will help to change future practice by integrating motivational interviewing in 
the outpatient clinical practice setting. 
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APPENDIX A: 
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APPENDIX C: 
MEDICATION ADHERENCE RATING SCALE (MARS) 
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(Thompson et al., 2000).  
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